ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. (AVBP) priced its initial public offering on Jan 26, 2024 at $18.00 per share, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $575.2M. Goldman Sachs was lead-left underwriter, joined by Jefferies and Citigroup. Mintz advised the company and Latham & Watkins advised the underwriters.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company developing medicines for cancer patients. Its lead candidate is furmonertinib, and it is also advancing a pipeline that includes next-generation antibody drug conjugates, with an initial focus on solid tumors.

Status

IPO

Ticker

AVBP

Exchange

Nasdaq Global Market

Priced

Jan 26, 2024

IPO price

$18.00

Market cap at IPO price

$575.2M

First filed

Jan 5, 2024

Underwriters

Goldman Sachs, Jefferies and Citigroup

Company counsel

Mintz

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

PA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.